Early markers of HIV-1 disease progression in a prospective cohort of seroconverters in Bangkok, Thailand: Implications for vaccine trials

Journal of Acquired Immune Deficiency Syndromes

Volumn 36, Issue 3, 2004, Pages 853-860

  Buchacz, Kate ^a,b   Hu, Dale J ^b   Vanichseni, Suphak ^c   Mock, Philip A ^d   Chaowanachan, Thanyanan ^d   Srisuwanvilai, La Ong ^c   Gvetadze, Roman ^b   Van Griensven, Frits ^b,d   Tappero, Jordan W ^b,d   Kitayaporn, Dwip ^e   Kaewkungwal, Jaranit ^e   Choopanya, Kachit ^c   Mastro, Timothy D ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Bangkok Metropolitan Administration   (Thailand)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Early HIV disease progression; HIV 1 vaccine endpoints, vaccine efficacy

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS RNA;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEROCONVERSION; THAILAND; TREATMENT PLANNING; VIRUS LOAD;

ADULT; AIDS VACCINES; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; PROSPECTIVE STUDIES; RNA, VIRAL; THAILAND; TIME FACTORS;

EID: 3042813641     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200407010-00013     Document Type: Article

References (54)

1. Wagner R, Shao Y, Wolf H. Correlates of protection, antigen delivery and molecular epidemiology: basics for designing an HIV vaccine. Vaccine. 1999;17:1706-1710.
2. Cohen J. AIDS vaccine trial produces disappointment and confusion. Science. 2003;299:1290-1291.
3. McCarthy M. AIDS vaccine fails in Thai trial. Lancet. 2003;262:1728.
4. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001;292:69-74.
5. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 2000;290:486-492.
6. Rida W, Fast P, Hoff R, et al. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:195-203.
7. Hu DJ, Vitek CR, Bartholow B, Mastro TD. Key issues for a potential human immunodeficiency virus vaccine. Clin Infect Dis. 2003;36:638-644.
8. Margolick JB, Farzadegan H, Hoover DR, et al. Relationship between infectious cell-associated human immunodeficiency virus type 1 load, T lymphocyte subsets, and stage of infection in homosexual men. J Infect Dis. 1996;173:468-471.
9. Katzenstein TL, Pedersen C, Nielsen C, et al. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS. 1996;10:167-173.
10. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
11. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
12. Gilbert PB, DeGruttola V, Hudgens MG, et al. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate endpoints in phase 3 trials. J Infect Dis. 2003;188:179-193.
13. Gilbert PB, DeGruttola V, Hammer SM, et al. Virologic and regimen termination surrogate endpoints in AIDS clinical trials. JAMA. 2001;285:777-784.
14. Kitayaporn D, Uneklabh C, Weniger BG, et al. HIV-1 incidence determined retrospectively among drug users in Bangkok, Thailand. AIDS. 1994;8:1443-1450.
15. Vanichseni S, Kitayapom D, Mastro TD, et al. Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok. Thailand. AIDS. 2001;15:397-405.
16. Francis DP, Heyward WL, Popovic V, et al. Candidate HIV/AIDS vaccines: lessons learned from the world's first phase III efficacy trials. AIDS. 2003;17:147-156.
17. Vanichseni S, Tappero JW, Pitisuttitham P, et al. Recruitment, screening and baseline epidemiologic characteristics of injection drug users enrolled in the AIDSVAX® B/E HIV vaccine trial in Bangkok, Thailand: Comparison of characteristics with a preparatory cohort study. AIDS. (In press)
18. Hu DJ, Vanichseni S, Mastro TD, et al. Viral load differences in early infection with two HIV-1 subtypes. AIDS. 2001;15:683-691.
19. Subbarao S, Vanichseni S, Hu DJ, et al. Genetic characterization of incident HIV-1 subtype E and B strains from a prospective cohort of injecting drug users in Bangkok, Thailand. AIDS Res Hum Retroviruses. 2000;16:699-707.
20. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979;74:829-836.
21. Diggle PJ, Liang K, Zeger SL. Analysis of Longitudinal Data. Oxford: Clarendon Press; 1994.
22. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS. 2001;15:2251-2257.
23. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
24. 6/l. AIDS. 2002;16:1371-1381.
25. Centers for Disease Control and Prevention. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Morb Mortal Wkly Rep. 2002;51(No. RR-7):1-55.
26. Alliston PD. Survival Analyses Using the SAS System: A Practical Guide. Cary, NC: SAS Publications; 1995.
27. Brettle RP, McNeil AJ, Burns S, et al. Progression of HIV: follow-up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983-1985. AIDS. 1996;10:419-430.
28. The Italian Seroconversion Study. Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. AIDS. 1992;6:421-426.
29. Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001;344:720-725.
30. Schacker TW, Hughes JP, Shea T, et al. Biological and virologic characteristics of primary HIV infection. Ann Intern Med. 1998;128:613-620.
31. + T-lymphocyte counts in the first year of HIV-1 infection. J Acquir Immune Defic Syndr. 1999;22:437-444.
32. Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J Infect Dis. 2000;181:872-880.
33. Hubert JB, Burgard M, Dussaix E, et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. AIDS. 2000;14:123-131.
34. Celum CL, Buchbinder SP, Donnell D, et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis. 2001;183:23-35.
35. Graziosi C, Soudeyns H, Rizzardini GP, et al. Immunopathogenesis of HIV infection. AIDS Res Hum Retroviruses. 1998;14(Suppl 2):S135-S142.
36. Fauci A. Host factors and the pathogenesis of HIV-induced disease. Nature. 1996;384:529-534.
37. Haynes BF, Pantaleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 1996;271:324-328.
38. Hu DJ, Byers RJ, Fleming PL, et al. Characteristics of persons with late AIDS diagnosis in the United States. Am J Prev Med. 1995;11:114-119.
39. Howard RR, Fasano CS, Frey L, et al. Reference intervals of CD3, CD4, CD8, CD4/CD8, and absolute CD4 values in Asian and non-Asian populations. Cytometry. 1996;26:231-232.
40. Anastos K, Gange SJ, Lau B, et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr. 2000;24:218-226.
41. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet. 1998;352:1510-1511.
42. Veugelers PJ, Page KA, Tindall B, et al. Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol. 1994;140:747-758.
43. Mulherin SA, O'Brien TR, Ioannidis JP, et al. Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS. 2003;17:377-387.
44. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995;122:573-579.
45. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clin Trials. 2001;22:485-502.
46. Delta Coordinating Committee and Virology Group. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. AIDS. 1999;13:565-573.
47. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate endpoints: a meta-analysis. AIDS Res Hum Retroviruses. 2000;16:1123-1133.
48. Gilbert PB, Self SG, Ashby MA. Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types. Biometrics. 1998;54:799-814.
49. Bogard E, Kuntz KM. The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic model. J Acquir Immune Defic Syndr. 2002;29:132-141.
50. Timaeus IM. Impact of the HIV epidemic on mortality in sub-Saharan Africa: evidence from national surveys and censuses. AIDS. 1998;12(Suppl 1):S15-S27.
51. Anderson RM, Swinton J, Garnett GP. Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection. Proc R Soc Lond B Biol Sci. 1995;261:147-151.
52. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921-929.
53. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996;335:1621-1629.
54. Weidle PJ, Mastro TD, Grant AD, et al. HIV/AIDS treatment and HIV vaccines for Africa. Lancet. 2002;359:2261-2267.